Last reviewed · How we verify
KLH; Peptides; Dendritic Cells
At a glance
| Generic name | KLH; Peptides; Dendritic Cells |
|---|---|
| Sponsor | Dr. Nina Bhardwaj |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence (PHASE2)
- Ovarian Dendritic Cell Vaccine Trial (PHASE2)
- A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma (PHASE2)
- Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients (PHASE2)
- Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood (PHASE1, PHASE2)
- IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma (PHASE1, PHASE2)
- Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KLH; Peptides; Dendritic Cells CI brief — competitive landscape report
- KLH; Peptides; Dendritic Cells updates RSS · CI watch RSS
- Dr. Nina Bhardwaj portfolio CI